NSE: ZYDUSWELL · 6 November 2026
- Zydus Wellness Ltd. (ZYDUSWELL) moved lower by 1.29% to close at ₹468.60 on Thursday, retreating from its intra-day high of ₹479.65 and touching a low of ₹465.10.
- Zydus Wellness submitted its financial results for the quarter and half year ended September 30, 2026, reporting a consolidated net sales jump of 74.6% to ₹11,227 million compared to ₹6,429 million in the corresponding period of the previous year. EBITDA for the quarter rose 271.7% to ₹855 million, supported by double-digit growth across key brands such as Everyuth, Sugar Free, and Complan.
- Trading volume was 0.48 times the 20-day average daily volume.
Why is Zydus Wellness share price falling on 6 November 2026?
Zydus Wellness Ltd. (ZYDUSWELL) moved lower by 1.29% to close at ₹468.60 on Thursday, retreating from its intra-day high of ₹479.65 and touching a low of ₹465.10.
The broader market demonstrated a strong recovery, with the Nifty benchmark advancing 2.01%, while the Nifty FMCG sector benchmark gained 0.67%. Zydus Wellness underperformed both the wider market and its sector peers, extending its recent retracement following a prior session return of -2.88% and a 20-day return of -4.86%, despite trading well above its 52-week low of ₹367.55.
While the company's robust Q2 financial results released on November 3, 2026—highlighting a 74.6% increase in consolidated net sales to ₹11,227 million—continue to provide medium-term fundamental context, today's downward price action appears primarily driven by ongoing profit-taking and low institutional trading interest following recent sessions of weakness rather than any fresh operational catalyst.
1.37 lakh shares traded by 6 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.85 lakh shares (0.48 times). The five-day average daily volume was 8.59 lakh shares. Separately, the NSE report for 6 November 2026 showed 55,183 shares delivered, representing 40.39% of that day’s traded volume. The same report recorded 12,408 trades.
The stock declined 1.29% on thin trading volumes that stood at less than half of its 20-day average, extending a short-term pullback in the absence of any fresh same-day catalysts.
Latest Company Developments
Zydus Wellness submitted its financial results for the quarter and half year ended September 30, 2026, reporting a consolidated net sales jump of 74.6% to ₹11,227 million compared to ₹6,429 million in the corresponding period of the previous year. EBITDA for the quarter rose 271.7% to ₹855 million, supported by double-digit growth across key brands such as Everyuth, Sugar Free, and Complan.
Strong quarterly performance and margin expansion directly impact fundamental valuation and institutional earnings expectations.
In response to an exchange clarification request regarding a media report on an FSSAI notice over product claims, the company confirmed it received the notice on September 24, 2026, and submitted its response on October 4, 2026. The company reiterated that product label statements are factual and scientifically substantiated, noting no material financial impact.
Clarifying regulatory inquiries helps alleviate market uncertainty regarding potential compliance risks or operational disruptions.
The company announced the appointment of Mr. Kapil Sharma as the Chief Revenue Officer, forming part of the senior management team. This strategic addition aims to strengthen commercial operations and distribution channels across domestic and digital markets.
Leadership enhancements in revenue-focused roles support execution capabilities across core consumer portfolios.
Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Significant increase in volume has been observed in Zydus Wellness Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Zydus Wellness Limited has submitted their response.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 18.72% on 30 September 2026. This compares with 18.73% on 30 June 2026, a change of -0.01 percentage points.
The filing reported 24 MF/UTI holders.
Research & Brokerage Views
Maintained a Buy rating following mixed quarterly numbers, citing long-term growth potential across core wellness and personal care brands.
What to Watch Next
- Execution progress and volume growth across the Everyuth and Sugar Free brand portfolios
- Adoption and performance of newly launched protein snacking products like RiteBite Max Protein Crunchy Cookies
- Further regulatory updates regarding product labeling compliance and FSSAI inquiries
- Institutional delivery trends relative to the 20-day average volume
Other Dated Coverage
- Zydus Wellness Share Price Jumps 8.72% Intraday, Closes 2.08% Higher | 3 November 2026 — 3 November 2026
- Zydus Wellness Share Price Today: Why ZYDUSWELL Is Falling 1.78% | 28 October 2026 — 28 October 2026
More Zydus Wellness news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Wellness company news?
Zydus Wellness submitted its financial results for the quarter and half year ended September 30, 2026, reporting a consolidated net sales jump of 74.6% to ₹11,227 million compared to ₹6,429 million in the corresponding period of the previous year. EBITDA for the quarter rose 271.7% to ₹855 million, supported by double-digit growth across key brands such as Everyuth, Sugar Free, and Complan.
How strong was Zydus Wellness’s trading volume?
1.37 lakh shares traded, 0.48 times the 20-day average daily volume. The price and volume data are dated 6 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.